Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma - PubMed (original) (raw)

Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma

Harold F Dvorak. Am J Pathol. 2003 Jun.

No abstract available

PubMed Disclaimer

Figures

Figure 1.

Figure 1.

a and b: Line 10 tumor cells 48 hours after transplant into the subcutaneous space of syngeneic strain 2 guinea pigs. Fibrin forms a water-trapping gel (F) that serves as a provisional stroma that separates tumor cells into discrete islands and that provides a favorable matrix for fibroblast (white arrows) and endothelial cell migration. c and d: Immunohistochemical demonstration of fibrin (brown staining) in guinea pig line 1 and human colorectal adenocarcinoma, respectively. e and f: Blood vessels (arrows) supplying line 10 guinea pig tumors are hyperpermeable to circulating macromolecular fluoresceinated dextran. g: Miles assay illustrating permeability to Evans blue-albumin complex at sites of intradermal injections of the following: (top, left to right) neutralizing anti-VEGF-A antibody, line 10 guinea pig tumor ascites fluid, mix of line 10 tumor ascites fluid and control IgG, mix of tumor ascites fluid and neutralizing anti-VEGF-A antibody. Bottom: line 1 tumor ascites fluid, mix of line 1 tumor ascites fluid and control IgG, and mix of line 1 tumor ascites fluid and neutralizing anti-VEGF-A antibody. h: Fibroblasts and blood vessels (black arrows) invade line 1 tumor fibrin gel, replacing it with fibrous connective tissue. i: Fibroblasts (arrows) migrate through fibrin gel (F) in vitro. j: Implanted fibrin gel (F) in subcutaneous space is replaced by ingrowth of fibroblasts and new blood vessels, creating granulation-like vascular connective tissue. Scale bars, 25 μm (b,i); 50 μm (a,c,d,h); 100 μm (e,f,j). e–g: Reprinted from Curr Top Microbiol Immunol 1999, 237:97–132 by copyright permission of Springer-Verlag GmbH & Co. KG; j reprinted from Lab Invest 1987, 57:673–686 by permission of Lippincott Williams & Wilkins, copyright The United States and Canadian Academy of Pathology, Inc.

Figure 2.

Figure 2.

Angiogenic response to Ad-VEGF-A164 in the ears of nude mice at the indicated times and magnifications. (Reprinted from Cold Spring Harbor Symp Quant Biol 2002, 67:227–237 by copyright permission of Cold Spring Harbor Laboratory Press.).

Figure 3.

Figure 3.

Electron micrographs 3 days after local Ad-VEGF-A164 injection and 20 minutes after i.v. injection of ferritin tracer. a: Hyperpermeable venule lined by endothelial cells of normal height, illustrating two prominent VVOs (collections of vesicles/vacuoles) that span endothelial cell cytoplasm from lumen (L) to abluminal basal lamina (BL). Note ferritin particles in vascular lumen, in VVO vesicles and vacuoles, and beneath BL (black dots, encircled). b: Mother vessel with greatly thinned endothelium spanned by four or fewer VVO vesicles/vacuoles. Note ferritin in these vesicles and vacuoles but tight junctions (arrows) remain closed and do not admit tracer. Bars, 200 nm. (Reprinted from Lab Invest 2000, 80:99–115 by permission of Lippincott Williams & Wilkins, copyright The United States and Canadian Academy of Pathology, Inc.)

Figure 4.

Figure 4.

Mother vessels induced by Ad-VEGF-A164 (a–j), MOT tumor (k) and healing skin wound (l). a: Whole mount of colloidal carbon-perfused vascular bed. Mother vessels appear as enlarged segments of much smaller, normal venules. b: Confocal microscopic image of mother vessel stained for pericytes with an antibody to α-smooth-muscle actin. Note incomplete pericyte covering, especially over segments of greatest vessel enlargement. c: Developing mother vessels illustrating pericyte detachment (arrows). d: Mother vessel with detached pericyte (arrow) and activated endothelial cells whose large nuclei bulge into the vascular lumen, creating a highly irregular surface. e and f: Serpentine mother vessels with irregular luminal surface and endothelial cell bridging (f, arrow). g: Mother vessels (m) embedded in fibrin (arrows) provisional stroma. h: Loss of laminin staining (arrows) in developing mother vessels (m). i and j: Endothelial cell bridging (i, arrows) in mother vessels in skeletal muscle and ear skin, respectively. k and l: Mother vessels in mouse ovarian tumor and healing rat skin wound, respectively. Note bridging in k (arrows) and fibrin in l (lower, between cells). Scale bars, 20 μm (b–l); 100 μm (a). a and b: Reprinted from Cold Spring Harbor Symp Quant Biol 2002, 67:227–237 by copyright permission of Cold Spring Harbor Laboratory Press; c,e,f,h–j reprinted from Lab Invest 2000, 80:99–115 by permission of Lippincott Williams & Wilkins, copyright The United States and Canadian Academy of Pathology, Inc.

Figure 5.

Figure 5.

Schematic diagram of mother vessel formation and evolution into daughter capillaries, vascular malformations and glomeruloid bodies. (Modified from Lab Invest 2000, 80:99–115 by permission of Lippincott Williams & Wilkins, copyright The United States and Canadian Academy of Pathology, Inc.)

Figure 6.

Figure 6.

GB formation and devolution. a: Whole mount illustrates two GBs in ear of mouse perfused with colloidal carbon (white arrows), supplied by afferent and efferent mother vessels (m). b: 1-μm Epon section illustrates focal accumulation of large primitive cells (arrow) in a developing mother vessel (m). c: Immunohistochemistry demonstrates that such cells are CD31-positive. d: Primitive GB develops as focal nodule (between brackets) of proliferating cells in the wall of a mother vessel (m), extending both into the lumen and out into the extravascular connective tissue. Lip, adipocyte. e: Immunohistochemical staining for entactin demonstrates abundant basement membrane in a large GB (bracket) as well as in a mother vessel (m) and, conversely, very little in a lymphatic (L). f and g: Maturing GBs divide mother vessels into multiple, much smaller vascular channels (arrows). White arrows in f and h indicate apoptotic bodies. h and i: Devolving GBs reorganize into more normal-appearing microvessels (black arrows). Scale bars, 25 μm (c–f, h–i); 50 μm (a,b); 100 μm (g). (Reprinted from Am J Pathol 2001, 158:1145–1160 by copyright permission of the American Society for Investigative Pathology.)

Figure 7.

Figure 7.

a and b: Vascular malformations induced by Ad-VEGF-A164 in ear skin at 35 and 131 days, respectively. L, giant lymphatics. c–f: Arteriogenesis following administration of Ad-VEGF-A164 in ear skin. Small arteries (c,d) enlarge by 6 to 7 days (e,f) accompanied by replication of endothelium and smooth muscle cells. Arrow (e), [3H]thymidine incorporated by a smooth-muscle cell. Scale bars, 50 μm (a,b); 15 μm (c–f). (Modified from Cold Spring Harbor Symp Quant Biol 2002, 67:227–237 by copyright permission of Cold Spring Harbor Laboratory Press.)

Figure 8.

Figure 8.

a–d: Giant lymphatics in mouse ear skin at indicated times after injection of Ad-VEGF-A164. Lymphatics were perfused with colloidal carbon and viewed macroscopically. e–g: 1-μm Epon sections of giant lymphatics at indicated times after Ad-VEGF-A164. Lymphatics were injected with colloidal carbon (e). Scale bars, 50 μm. (Reprinted form J Exp Med 2002, 196:1497–1506 by copyright permission of The Rockefeller University Press.)

Similar articles

Cited by

References

    1. Dvorak HF: Tumors: wounds that do not heal: similarities between tumor stroma generation and wound healing. N Engl J Med 1986, 315:1650-1659 - PubMed
    1. Dvorak H, Nagy J, Feng D, Dvorak A: Tumor architecture and targeted delivery. Abrams P Fritzberg A eds. Radioimmunotherapy of Cancer. 2000:pp 107-135 Marcel Dekker, Inc., New York
    1. Folkman J: Tumor angiogenesis. Adv Cancer Res 1985, 43:175-203 - PubMed
    1. Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. Exs 1997, 79:233-269 - PubMed
    1. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999, 237:97-132 - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources